These results suggest that the efficacy and safety of dabrafenib plus trametinib combination in patients with BRAF V600E-mutant metastatic NSCLC are comparable in a real-world setting and in clinical trials for both previously untreated and treated patients. Here, BRAF is linked to non-small cell lung carcinoma.